IGF-I and IGFBP-3 concentrations in the blood serum and lung cancer risk

T. Izycki, W. Naumnik, M. Ossolinska, E. Chyczewska (Bialystok, Poland)

Source: Annual Congress 2007 - Biology of thoracic malignancies
Session: Biology of thoracic malignancies
Session type: Electronic Poster Discussion
Number: 1826
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Izycki, W. Naumnik, M. Ossolinska, E. Chyczewska (Bialystok, Poland). IGF-I and IGFBP-3 concentrations in the blood serum and lung cancer risk. Eur Respir J 2007; 30: Suppl. 51, 1826

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A serum level of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 329s
Year: 2005

A serum level of IGF-I, IGF-II and IGFBP-3 in patients with small cell lung cancer (SCLC) during chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 86s
Year: 2006

Serum levels of STR-3 and TIMP-2 in lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002

Clinical significance of serum adipokines levels in lung cancer
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009

Serum levels of TGFβ and VEGF in lung cancer patients and healthy subjects
Source: Eur Respir J 2004; 24: Suppl. 48, 43s
Year: 2004

Relation between bone metastasis in lung cancer and serum IL-6 levels
Source: Annual Congress 2008 - Various aspects of thoracic oncology
Year: 2008

Clinical significance of serum osteopontin levels in lung cancer
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012

The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 82s
Year: 2004

Serum levels of sFas and sFasL during chemotherapy of lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 329s
Year: 2005

The study on the association of serum C-reactive protein level with the risk of lung cancer
Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours
Year: 2009


Serum levels of vascular endothelial growth factor in lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 77s
Year: 2004

Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011

Plasma D-dimer level and stage of primary lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 250s
Year: 2003

Determinants of serum leptin and adiponectin levels in patients with COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 59s
Year: 2005

Evaluation of serum levels of Sirtuin-1 in lung cancer patients
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020


CEA levels in the serum and induced sputum of lung cancer patients
Source: Eur Respir J 2005; 26: Suppl. 49, 324s
Year: 2005

Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011

The clinical significance of serum interleukin 18 concentration in lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 394s
Year: 2003

Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008